GLP1R and obesity due to melanocortin 4 receptor deficiency: We followed several principles of clinical trials, including a clearly-defined intervention strategy (ie, 3 groups of weight loss: <2%, 2%-10%, and >10%) over 1 year using the antiobesity medications (ie, orlistat, sibutramine, GLP-1 receptor agonists, and rimonabant), a clearly-defined target population (ie, patients with obesity undergoing joint replacement), and well-defined study outcomes (ie, revision following joint replacements).